Density-clustering of continuous gravitational wave candidates from large surveys

Searches for continuous gravitational waves target nearly monochromaticgravitational wave emission from e.g. non-axysmmetric fast-spinning neutronstars. Broad surveys often require to explicitly search for a very large numberof different waveforms, easily exceeding $\sim10^{17}$ templates. In suchcases, for practical reasons, only the top, say $\sim10^{10}$, results aresaved and followed-up through a hierarchy of stages. Most of these candidatesare not completely independent of neighbouring ones, but arise due to somecommon cause: a fluctuation, a signal or a disturbance. By judiciouslyclustering together candidates stemming from the same root cause, thesubsequent follow-ups become more effective. A number of clustering algorithmshave been employed in past searches based on iteratively finding symmetric andcompact over-densities around candidates with high detection statistic values.The new clustering method presented in this paper is a significant improvementover previous methods: it is agnostic about the shape of the over-densities, isvery efficient and it is effective: at a very high detection efficiency, it hasa noise rejection of $99.99\%$ , is capable of clustering two orders ofmagnitude more candidates than attainable before and, at fixed sensitivity itenables more than a factor of 30 faster follow-ups. We also demonstrate how tooptimally choose the clustering parameters.<br

Plasma amyloid concentration in Alzheimer's disease: performance of a high-throughput amyloid assay in distinguishing Alzheimer's disease cases from controls

BACKGROUND: Collection of cerebrospinal fluid (CSF) for measurement of amyloid-β (Aβ) species is a gold standard in Alzheimer's disease (AD) diagnosis, but has risks. Thus, establishing a low-risk blood Aβ test with high AD sensitivity and specificity is of outmost interest. OBJECTIVE: We evaluated the ability of a commercially available plasma Aβ assay to distinguish AD patients from biomarker-healthy controls. METHOD: In a case-control design, we examined plasma samples from 44 AD patients (A + N+) and 49 controls (A-N-) from a memory clinic. AD was diagnosed using a combination of neuropsychological examination, CSF biomarker analysis and brain imaging. Total Aβ40 and total Aβ42 in plasma were measured through enzyme-linked immunosorbent assay (ELISA) technology using ABtest40 and ABtest42 test kits (Araclon Biotech Ltd.). Receiver operating characteristic (ROC) analyses with outcome AD were performed, and sensitivity and specificity were calculated. RESULTS: Plasma Aβ42/40 was weakly positively correlated with CSF Aβ42/40 (Spearman's rho 0.22; p = 0.037). Plasma Aβ42/40 alone was not able to statistically significantly distinguish between AD patients and controls (AUC 0.58; 95% CI 0.46, 0.70). At a cut-point of 0.076 maximizing sensitivity and specificity, plasma Aβ42/40 had a sensitivity of 61.2% and a specificity of 63.6%. CONCLUSION: In this sample, the high-throughput blood Aβ assay was not able to distinguish well between AD patients and controls. Whether or not the assay may be useful in large-scale epidemiological settings remains to be seen

A Phase I trial of talazoparib in patients with advanced hematologic malignancies

Aim: The objective of this study was to establish the maximum tolerated dose (MTD), safety, pharmacokinetics, and anti-leukemic activity of talazoparib. Patients & methods: This Phase I, two-cohort, dose-escalation trial evaluated talazoparib monotherapy in advanced hematologic malignancies (cohort 1: acute myeloid leukemia/myelodysplastic syndrome; cohort 2: chronic lymphocytic leukemia/mantle cell lymphoma). Results: Thirty-three (cohort 1: n = 25; cohort 2: n = 8) patients received talazoparib (0.1-2.0 mg once daily). The MTD was exceeded at 2.0 mg/day in cohort 1 and at 0.9 mg/day in cohort 2. Grade ≥3 adverse events were primarily hematologic. Eighteen (54.5%) patients reported stable disease. Conclusion: Talazoparib is relatively well tolerated in hematologic malignancies, with a similar MTD as in solid tumors, and shows preliminary anti leukemic activity.Clinical trial registration: NCT01399840 (ClinicalTrials.gov)

Anisotropic scattering and quantum magnetoresistivities of a periodically modulated 2D electron gas

We calculate the longitudinal conductivities of a two-dimensional noninteracting electron gas in a uniform magnetic field and a lateral electric or magnetic periodic modulation in one spatial direction, in the quantum regime. We consider the effects of the electron-impurity scattering anisotropy through the vertex corrections on the Kubo formula, which are calculated with the Bethe-Salpeter equation, in the self-consistent Born approximation. We find that due to the scattering anisotropy the band conductivity increases, and the scattering conductivities decrease and become anisotropic. Our results are in qualitative agreement with recent experiments.Comment: 19 pages, 8 figures, Revtex, to appear in Phys. Rev.

Weak Localization and Integer Quantum Hall Effect in a Periodic Potential

We consider magnetotransport in a disordered two-dimensional electron gas in the presence of a periodic modulation in one direction. Existing quasiclassical and quantum approaches to this problem account for Weiss oscillations in the resistivity tensor at moderate magnetic fields, as well as a strong modulation-induced modification of the Shubnikov-de Haas oscillations at higher magnetic fields. They do not account, however, for the operation at even higher magnetic fields of the integer quantum Hall effect, for which quantum interference processes are responsible. We then introduce a field-theory approach, based on a nonlinear sigma model, which encompasses naturally both the quasiclassical and quantum-mechanical approaches, as well as providing a consistent means of extending them to include quantum interference corrections. A perturbative renormalization-group analysis of the field theory shows how weak localization corrections to the conductivity tensor may be described by a modification of the usual one-parameter scaling, such as to accommodate the anisotropy of the bare conductivity tensor. We also show how the two-parameter scaling, conjectured as a model for the quantum Hall effect in unmodulated systems, may be generalized similarly for the modulated system. Within this model we illustrate the operation of the quantum Hall effect in modulated systems for parameters that are realistic for current experiments.Comment: 15 pages, 4 figures, ReVTeX; revised version with condensed introduction; two figures taken out; reference adde